Exact Sciences has entered into an exclusive agreement with Freenome, a biotechnology company pioneering an early cancer detection platform, the company announced recently.

According to a release, Exact Sciences will acquire exclusive rights in the United States to current and future versions of Freenome’s blood-based, single-indication, colorectal cancer (CRC) screening tests.

“This exclusive license expands our leadership in cancer screening with the addition of blood-based options,” Exact Sciences Chairman and CEO Kevin Conroy said in a statement. “We’re now able to offer a complementary blood-based option to the over 50 million unscreened Americans, supported by our broad commercial reach, ExactNexus technology platform, and deep relationships with health systems and payers.”

Under the agreement, Freenome will receive $75 million in cash payable by November 2025.